Literature DB >> 18178218

Disruption of ROCK1 gene attenuates cardiac dilation and improves contractile function in pathological cardiac hypertrophy.

Jianjian Shi1, Yi-Wei Zhang, Lelia J Summers, Gerald W Dorn, Lei Wei.   

Abstract

The development of left ventricular cardiomyocyte hypertrophy in response to increased hemodynamic load and neurohormonal stress is initially a compensatory response. However, persistent stress eventually leads to dilated heart failure, which is a common cause of heart failure in human hypertensive and valvular heart disease. We have recently reported that Rho-associated coiled-coil containing protein kinase 1 (ROCK1) homozygous knockout mice exhibited reduced cardiac fibrosis and cardiomyocyte apoptosis, while displaying a preserved compensatory hypertrophic response to pressure overload. In this study, we have tested the effects of ROCK1 deficiency on cardiac hypertrophy, dilation, and dysfunction. We have shown that ROCK1 deletion attenuated left ventricular dilation and contractile dysfunction, but not hypertrophy, in a transgenic model of Galphaq overexpression-induced hypertrophy which represents a well-characterized and highly relevant genetic mouse model of pathological hypertrophy. Although the development of cardiomyocyte hypertrophy was not affected, ROCK1 deletion in Galphaq mice resulted in a concentric hypertrophic phenotype associated with reduced induction of hypertrophic markers indicating that ROCK1 deletion could favorably modify hypertrophy without inhibiting it. Furthermore, ROCK1 deletion also improved contractile response to beta-adrenergic stimulation in Galphaq transgenic mice. Consistent with this observation, ROCK1 deletion prevented down-regulation of type V/VI adenylyl cyclase expression, which is associated with the impaired beta-adrenergic signaling in Galphaq mice. The present study establishes for the first time a role for ROCK1 in cardiac dilation and contractile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18178218      PMCID: PMC2728597          DOI: 10.1016/j.yjmcc.2007.11.018

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  40 in total

1.  Cardiomyocyte apoptosis induced by Galphaq signaling is mediated by permeability transition pore formation and activation of the mitochondrial death pathway.

Authors:  J W Adams; A L Pagel; C K Means; D Oksenberg; R C Armstrong; J H Brown
Journal:  Circ Res       Date:  2000-12-08       Impact factor: 17.367

2.  Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases.

Authors:  T Ishizaki; M Uehata; I Tamechika; J Keel; K Nonomura; M Maekawa; S Narumiya
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

3.  Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice.

Authors:  Y Sakata; B D Hoit; S B Liggett; R A Walsh; G W Dorn
Journal:  Circulation       Date:  1998-04-21       Impact factor: 29.690

4.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes.

Authors:  N Wettschureck; H Rütten; A Zywietz; D Gehring; T M Wilkie; J Chen; K R Chien; S Offermanns
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

5.  Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy.

Authors:  Tetsuhiko Yanazume; Koji Hasegawa; Hiromichi Wada; Tatsuya Morimoto; Mitsuru Abe; Teruhisa Kawamura; Shigetake Sasayama
Journal:  J Biol Chem       Date:  2001-12-05       Impact factor: 5.157

6.  Epsilon protein kinase C in pathological myocardial hypertrophy. Analysis by combined transgenic expression of translocation modifiers and Galphaq.

Authors:  G Wu; T Toyokawa; H Hahn; G W Dorn
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

7.  MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq.

Authors:  Tetsuo Minamino; Toshiaki Yujiri; Naohiro Terada; George E Taffet; Lloyd H Michael; Gary L Johnson; Michael D Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

8.  Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts.

Authors:  Naohiko Kobayashi; Shigeo Horinaka; Shin-ichiro Mita; Shigefumi Nakano; Takeaki Honda; Kohtaro Yoshida; Tsutomu Kobayashi; Hiroaki Matsuoka
Journal:  Cardiovasc Res       Date:  2002-09       Impact factor: 10.787

9.  RGS4 reduces contractile dysfunction and hypertrophic gene induction in Galpha q overexpressing mice.

Authors:  J H Rogers; A Tsirka; A Kovacs; K J Blumer; G W Dorn; A J Muslin
Journal:  J Mol Cell Cardiol       Date:  2001-02       Impact factor: 5.000

10.  Inhibition of Rho family GTPases by Rho GDP dissociation inhibitor disrupts cardiac morphogenesis and inhibits cardiomyocyte proliferation.

Authors:  Lei Wei; Kyoko Imanaka-Yoshida; Lu Wang; Song Zhan; Michael D Schneider; Francesco J DeMayo; Robert J Schwartz
Journal:  Development       Date:  2002-04       Impact factor: 6.868

View more
  35 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

2.  Spatial variability in T-tubule and electrical remodeling of left ventricular epicardium in mouse hearts with transgenic Gαq overexpression-induced pathological hypertrophy.

Authors:  Wen Tao; Jianjian Shi; Gerald W Dorn; Lei Wei; Michael Rubart
Journal:  J Mol Cell Cardiol       Date:  2012-06-21       Impact factor: 5.000

Review 3.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 4.  Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.

Authors:  Naoki Sawada; James K Liao
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

Review 5.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 6.  Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling.

Authors:  Gerald W Dorn
Journal:  Cardiovasc Res       Date:  2008-09-08       Impact factor: 10.787

Review 7.  Protective transcriptional mechanisms in cardiomyocytes and cardiac fibroblasts.

Authors:  Cameron S Brand; Janet K Lighthouse; Michael A Trembley
Journal:  J Mol Cell Cardiol       Date:  2019-04-28       Impact factor: 5.000

8.  Prevention of RhoA activation and cofilin-mediated actin polymerization mediates the antihypertrophic effect of adenosine receptor agonists in angiotensin II- and endothelin-1-treated cardiomyocytes.

Authors:  Asad Zeidan; Xiaohong Tracey Gan; Ashley Thomas; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2013-10-06       Impact factor: 3.396

9.  Focal adhesion kinase as a RhoA-activable signaling scaffold mediating Akt activation and cardiomyocyte protection.

Authors:  Dominic P Del Re; Shigeki Miyamoto; Joan Heller Brown
Journal:  J Biol Chem       Date:  2008-10-14       Impact factor: 5.157

10.  Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat.

Authors:  Claudia Mera; Iván Godoy; Renato Ramírez; Jackeline Moya; María Paz Ocaranza; Jorge E Jalil
Journal:  Ther Adv Cardiovasc Dis       Date:  2015-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.